NB.1.8.1 variant monitored by WHO as global spread accelerates in May 2025

What Is NB.1.8.1 and Why Are Global Health Agencies Tracking It in May 2025?

On May 23, 2025, the World Health Organization officially classified the COVID-19 subvariant NB.1.8.1 as a Variant Under Monitoring (VUM) due to its expanding presence across multiple countries and its possible implications for public health. Initially identified in China earlier this year, NB.1.8.1 has now been detected in the United States, India, Singapore, and several other countries. In the United States, the Centers for Disease Control and Prevention confirmed that the subvariant has been identified through genomic sequencing from multiple locations, including international airport screenings and domestic surveillance.

The lineage descends from the JN.1 family, itself a descendent of the BA.2.86 Omicron variant. This evolution is being watched closely by public health officials worldwide. While current assessments indicate a low global public health risk, experts caution that the subvariant’s rapid growth in sequenced cases merits ongoing attention and more data.

Where Has NB.1.8.1 Been Detected and How Fast Is It Spreading?

NB.1.8.1 was first sequenced in China during the first quarter of 2025. Since then, the subvariant’s prevalence has expanded substantially. According to the WHO’s latest global update issued on May 23, NB.1.8.1 constituted 10.7% of all SARS-CoV-2 samples sequenced globally during the last week of April. This marks a sharp increase from just 2.5% in late March, indicating a significant growth advantage over other circulating strains.

In the United States, the variant has been detected at airport screening stations in states including California, Virginia, New York, and Washington. Community-level transmission has been confirmed in Ohio, Rhode Island, and Hawaii, according to the CDC. India’s genomic surveillance agency INSACOG reported its first NB.1.8.1 detection in Tamil Nadu in April 2025. Public health authorities in Singapore have also acknowledged rising detection rates, although hospitalizations linked to the variant remain low as of this update.

What Are the Key Mutations in NB.1.8.1?

The NB.1.8.1 variant includes several mutations in the spike protein that are of interest to virologists and immunologists. Among these are A435S, V445H, and T478I—mutations that may enhance the virus’s ability to bind to the ACE2 receptor on human cells. Notably, the T478I mutation has appeared in earlier variants and is associated with increased transmissibility and potential immune escape characteristics. Early laboratory analyses suggest a moderate reduction in the neutralizing ability of antibodies from prior infection or vaccination, estimated at 1.5 to 1.6-fold compared to JN.1.

This level of immune evasion is in line with other JN.1 sublineages and does not presently indicate a major breakthrough in vaccine escape. Nevertheless, researchers are continuing in vitro testing to better understand the functional implications of these mutations on viral replication and immune resistance.

What Symptoms Are Linked to NB.1.8.1 Infections?

Clinical reports from the CDC and other national health agencies suggest that symptoms associated with NB.1.8.1 closely mirror those of earlier Omicron variants. Commonly reported symptoms include mild to moderate fever, sore throat, nasal congestion, fatigue, muscle pain, and headaches. A small subset of patients has also reported gastrointestinal issues, including nausea and diarrhea.

So far, most cases have been classified as mild, especially among vaccinated individuals. No statistically significant increase in hospital admissions or intensive care requirements has been documented. Public health authorities have indicated that the pattern of illness remains consistent with previously circulating Omicron subvariants, which have generally caused less severe disease than earlier pandemic variants like Delta.

What Are WHO and CDC Saying About the Risk Level?

In its latest variant tracking bulletin, the World Health Organization stated that NB.1.8.1 shows a “notable growth advantage and moderate immune evasion,” but stressed that there is currently no evidence to suggest increased severity or a change in clinical management practices. Based on available data, the global public health risk associated with NB.1.8.1 remains categorized as low. WHO officials have recommended continued surveillance and sequencing efforts to monitor the subvariant’s evolution.

The Centers for Disease Control and Prevention has not yet designated NB.1.8.1 as a Variant of Concern or a Variant of Interest but continues to monitor its spread through the National Wastewater Surveillance System and Genomic Surveillance Network. Federal officials have urged clinicians to remain aware of emerging variant trends but have not issued any new treatment or testing guidelines.

Are Current Vaccines Effective Against NB.1.8.1?

Existing mRNA-based COVID-19 vaccines, including those developed by Moderna and Pfizer-BioNTech, are expected to retain substantial efficacy in preventing severe illness, hospitalization, and death from NB.1.8.1. The U.S. Food and Drug Administration has already approved the formulation of a new booster vaccine targeted at JN.1-based variants for distribution in the fall and winter 2025 season. Experts expect this update will enhance protection against NB.1.8.1 and its sibling sublineages.

Health authorities continue to recommend timely booster doses, particularly for older adults, people with chronic illnesses, and healthcare workers. Despite the variant’s ability to partially evade antibody responses, T-cell immunity and existing neutralizing antibody levels are believed to still offer significant protection against progression to severe disease.

What Public Health Measures Are Being Recommended?

Although no new mandates have been introduced as of May 24, public health departments in affected regions have issued advisories encouraging residents to adopt precautionary behaviors. These include mask-wearing in indoor public spaces, especially in healthcare settings, regular hand hygiene, and voluntary isolation when symptomatic. Individuals are also being encouraged to stay up to date with booster vaccinations and to seek testing promptly if COVID-like symptoms develop.

Hospitals and long-term care facilities are being advised to review their infection prevention protocols and ensure that COVID-specific response plans remain active, especially ahead of the potential summer and fall waves. At the national level, no changes to border policies or travel advisories have been announced in response to NB.1.8.1.

Why This Variant Matters in the Broader COVID-19 Landscape

The emergence and spread of NB.1.8.1 reflect the virus’s ongoing adaptation in a global population with heterogeneous levels of immunity. With pandemic-era restrictions largely lifted, continued genomic surveillance, booster adaptation, and localized public health responses remain essential to managing the next phase of SARS-CoV-2. The relatively mild disease severity observed so far offers reassurance, but the variant’s rapid growth signals the need for vigilance, especially in communities with low booster coverage or lagging healthcare infrastructure.

For now, public health experts emphasize that NB.1.8.1 is not a cause for panic, but a reminder that the virus continues to evolve and that mitigation efforts cannot be entirely abandoned. As with previous waves, the trajectory of this variant will depend heavily on vaccination rates, public behavior, and timely data collection.